OSL & Industry News

 
 
 

DoseWire: OSL signs exclusive distributor agreement with DoseVue NV

Oncology Systems Limited (OSL) would like to announce they have signed an exclusive agreement with DoseVue NV, to distribute an in-vivo dosimetry product DoseWire ™ Series 200, to radiotherapy centres within the UK and Ireland.

 

DoseVue’s unique technology uses fibre optic filaments coated in a light-emitting material that fluoresces when exposed to radiation. This allows for the real-time, accurate measurement of the actual dose delivered during radiation oncology procedures. The compact sensors of the DoseWire™ Series 200 can be easily positioned at up to four locations during procedures, applied on patient’s skin or introduced in natural and/or surgical cavities. CE marked as a medical device, the DoseWire™ Series 200 can be used for a range of applications, including brachytherapy and intraoperative radiation therapy (IORT).

 

“OSL are proud to be offering this unique and innovative technology for in-Vivo Dosimetry. DoseWire is suitable for multiple applications with fibre optic precision and accuracy. A great addition to our portfolio”, adds Stuart Southgate, Commercial Manager, OSL.

The DoseWire Series 200 has been validated in the following clinical contexts:

  • HDR Brachytherapy (using lr-192)
  • Electron-based IORT
  • MRI Linac (6 MeV, 0.4 T maximum)
  • Stereotactic Radiosurgery
  • Contact therapy (Orthovoltage therapy)
  • Proton therapy (up to 62 MeV)

Contact OSL to find out more about the DoseWire Series 200.

 

You might be interested in